Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liraglutide vs metformin vs gliclazide MR for hepatic fat in type 2 diabetes mellitus with non-alcoholic fatty liver disease
ChiCTR-TRC-14004660Phase 4Not yet recruiting
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- Sep 2014
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of liraglutide, metformin and gliclazide in type 2 diabetes mellitus (T2DM) and metabolic dysfunction-associated steatotic liver disease (MASLD) (3 arms), sponsored by Nanjing Drum-Tower Hospital. Primary endpoints: Liver fat content and HbA1c. Planned start Sep 2014; status: not yet recruiting.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on ChiCTR-TRC-14004660.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-14004660.